ABSTRACT
PURPOSE: Xijiao Dihuang Tang (XJDHT) is a classical formula of traditional Chinese medicine constituted of Cornu Bubali, Rehmannia glutinosa (Gaertn.) DC., Paeonia lactiflora Pall., and Paeonia suffruticosa Andrews. It was first mentioned in the medical classic "Beiji Qianjin Yaofang" written by Simiao Sun in Tang Dynasty. It shows very strong antipyretic and anticoagulant effects and has been clinically applied to treat various type of blood loss, purple and black spots, heat stroke, and glossitis. Kawasaki disease (KD) is considered as a kind of acute febrile illness in children with systemic vasculitis as the main lesions. The aim of this research is to clarify whether XJDHT can play a protective role in KD. METHODS: A mouse model of Candida albicans water-soluble fraction (CAWS)-induced coronary arteritis and a KD cell model with tumor necrosis factor (TNF)-α induction were employed to investigate the potential effect and mechanism of XJDHT on coronary artery injury in KD. RESULTS: Data showed that XJDHT remarkably alleviated the coronary artery injury of KD mice, as evidenced by reduced inflammation and downregulated expression of pro-inflammatory cytokines interleukin (IL)-1ß and TNF-α. In vitro investigation showed that XJDHT could promote cell proliferation, inhibit cell apoptosis, and improve mitochondrial functions. Subsequent studies demonstrated that XJDHT rescued endothelial cell injury by PI3K/Akt-NFκB signaling pathway. Component analysis of XJDHT detected thirty-eight chemically active ingredients, including paeoniflorin, albiflorin, and paeoniflorigenone, which in in vitro experiments exhibited significant rescue effects on TNF-α-mediated endothelial cell injury. CONCLUSION: Our findings demonstrated that XJDHT mitigated coronary artery injury of KD through suppressing endothelial cell damage via PI3K/Akt-NFκB signaling.
Subject(s)
Coronary Artery Disease , Mucocutaneous Lymph Node Syndrome , Mice , Animals , Mucocutaneous Lymph Node Syndrome/drug therapy , Mucocutaneous Lymph Node Syndrome/pathology , Coronary Vessels , Tumor Necrosis Factor-alpha/metabolism , Proto-Oncogene Proteins c-akt , Phosphatidylinositol 3-Kinases , NF-kappa B , Disease Models, AnimalABSTRACT
INTRODUCTION/OBJECTIVES: Asian scores developed to predict unresponsiveness to intravenous immunoglobulin (IVIG) or development of coronary artery aneurysms (CAA) in patients with Kawasaki disease (KD) are not appropriate in Western populations. The purpose of this study is to develop 2 scores, to predict unresponsiveness to IVIG and development of CAA, appropriate for Spanish population. METHOD: Data of 625 Spanish children with KD collected retrospectively (2011-2016) were used to identify variables to develop the 2 scores of interest: unresponsiveness to IVIG and development of CAA. A statistical model selected best variables to create the scores, and scores were validated with data from 98 patients collected prospectively. RESULTS: From 625 patients of the retrospective cohort, final analysis was performed in 439 subjects: 37 developed CAA, and 212 were unresponsive to IVIG. For the score to predict CAA, a cutoff ≥ 8 was considered for high risk, considering a score system with a different weight for each of the eight variables. External validation showed a sensitivity of 22% and a specificity of 75%. The score to predict unresponsiveness to IVIG established a cutoff ≥ 8 for high risk, considering a score system with a different weight for each of the nine variables. External validation showed a sensitivity of 78% and a specificity of 50%. CONCLUSIONS: Two risk scores for KD were developed from Spanish population, to predict development of CAA and unresponsiveness to IVIG; validation in other cohorts could help to implement these tools in the management of KD in other Western populations.
Subject(s)
Coronary Aneurysm , Kava , Mucocutaneous Lymph Node Syndrome , Child , Humans , Infant , Mucocutaneous Lymph Node Syndrome/complications , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Retrospective Studies , Coronary Aneurysm/etiology , Coronary Aneurysm/epidemiology , Risk FactorsABSTRACT
BACKGROUND: Kawasaki disease (KD) is a major cause of coronary artery lesions (CALs) in children. Approximately 10% to 20% of children treated with intravenous immunoglobulin are intravenous immunoglobulin-resistant. This study evaluated the efficacy and safety of adding herbal medicine to conventional western medicines versus conventional western medicines alone for CALs in children with KD. METHODS: This study searched 9 electronic databases until August 31, 2021. The inclusion criteria were the randomized controlled trials (RCTs) that assessed the CALs in children with KD and compared integrative treatment with conventional western treatments. Two authors searched independently for RCTs, including eligible articles that fulfilled the inclusion criteria, extracted data, and assessed the methodological quality using the Cochrane risk of bias tool. Meta-analysis was conducted using Cochrane Collaboration's Review Manager 5.4 software. The effect size was presented as the risk ratio (RR), and the fixed-effect models were used to pool the results. RESULTS: The finally selected 12 studies included a total of 1030 KD patients. According to a meta-analysis, the integrative treatment showed better results than the conventional treatment in the CAL prevalence rate (RRâ=â2.00; 95% confidence interval [CI], 1.49-2.71; Pâ<â.00001), CAL recovery rate (RRâ=â1.27; 95% CI, 1.05-1.54; Pâ=â.02), and total effective rate (RRâ=â1.17; 95% CI, 1.11-1.23; Pâ<â.00001). Only 2 studies referred to the safety of the treatment. The asymmetrical funnel plot of the CAL prevalence rate indicated the possibility of potential publication bias. CONCLUSIONS: This review found the integrative treatment to be more effective in reducing the CAL prevalence rate and increasing the CAL recovery rate and total effective rate in KD patients than conventional western treatment. However, additional well-designed RCTs will be needed further to compensate restrictions of insufficient trials on safety, methodological quality, and publication bias.
Subject(s)
Mucocutaneous Lymph Node Syndrome , Plants, Medicinal , Child , Coronary Vessels , Herbal Medicine , Humans , Mucocutaneous Lymph Node Syndrome/complications , Mucocutaneous Lymph Node Syndrome/drug therapy , PhytotherapyABSTRACT
BACKGROUND: Kawasaki disease (KD) is an acute febrile vasculitis that often occurs in children under 5 years. Ptosis and muscle weakness associated with KD are rarely documented. CASE PRESENTATION: We present a case of KD with eyelid ptosis and muscle weakness in a 3-year-old boy. At admission, grade IV and grade III muscle strength were recorded for upper and lower limbs, respectively. Diminished patellar tendon reflex was noted. Laboratory evaluation showed hypokalemia with the serum potassium concentration of 2.62 mmol/L. Intravenous immunoglobulin (IVIG) and aspirin were initiated immediately accompanied with methylprednisolone for adjunctive therapy. Potassium supplement was administered at the same time, which resulted in the correction of hypokalemia on the 2nd day of admission but no improvement in ptosis and muscle weakness. Neostigmine testing, lumber puncture, electromyography, and cerebral and full spine MRI were performed, which, however, did not find evidence for neural and muscle diseases. On the 5th day, the fever was resolved. On the 6th day, eyelid ptosis disappeared. And on the 14th day, the muscle strength and muscle tension returned to normal, patellar tendon reflex could be drawn out normally, and the boy regained full ambulatory ability. CONCLUSIONS: KD might affect the neural and muscular systems, and KD complicated with eyelid ptosis and muscle weakness is responsive to the standard anti-inflammatory treatment plus adjunctive corticosteroid therapy.
Subject(s)
Blepharoptosis , Mucocutaneous Lymph Node Syndrome , Aspirin/therapeutic use , Blepharoptosis/etiology , Child , Child, Preschool , Humans , Immunoglobulins, Intravenous/therapeutic use , Male , Mucocutaneous Lymph Node Syndrome/complications , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapy , Muscle Weakness/etiologyABSTRACT
BACKGROUND: Kawasaki disease (KD) is a self-limiting acute systemic vasculitis occur mainly in infants and young children under 5 years old. Although the use of acetylsalicylic acid (AAS) in combination with intravenous immunoglobulin (IVIG) remains the standard therapy to KD, the etiology, genetic susceptibility genes and pathogenic factors of KD are still un-elucidated. PURPOSE: Current obstacles in the treatment of KD include the lack of standard clinical and genetic markers for early diagnosis, possible severe side effect of AAS (Reye's syndrome), and the refractory KD cases with resistance to IVIG therapy, therefore, this review has focused on introducing the current advances in the identification of genetic susceptibility genes, environmental factors, diagnostic markers and adjuvant pharmacological intervention for KD. RESULTS: With an overall update in the development of KD from different aspects, our current bioinformatics data has suggested CASP3, CD40 and TLR4 as the possible pathogenic factors or diagnostic markers of KD. Besides, a list of herbal medicines which may work as the adjunct therapy for KD via targeting different proposed molecular targets of KD have also been summarized. CONCLUSION: With the aid of modern pharmacological research and technology, it is anticipated that novel therapeutic remedies, especially active herbal chemicals targeting precise clinical markers of KD could be developed for accurate diagnosis and treatment of the disease.
Subject(s)
Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapy , Mucocutaneous Lymph Node Syndrome/genetics , Phytotherapy/methods , Adjuvants, Immunologic/therapeutic use , Adjuvants, Pharmaceutic/therapeutic use , Aspirin/therapeutic use , CD40 Antigens/genetics , Caspase 3/genetics , Child , Child, Preschool , Genetic Markers , Genetic Predisposition to Disease , Genome-Wide Association Study , Humans , Immunoglobulins, Intravenous/therapeutic use , Infant , Japan/epidemiology , Mucocutaneous Lymph Node Syndrome/epidemiology , Toll-Like Receptor 4/geneticsABSTRACT
RATIONALE: Kawasaki disease (KD) is an acute febrile illness predominantly affecting children less than 5 years of age and characterized by systemic inflammation in all medium-sized arteries. Adult-onset KD (AKD) is rare with only 105 case reports published. Recently, the efficacy of infliximab (IFX) for patients with refractory KD has been demonstrated. PATIENT CONCERNS: A previously healthy 24-year-old man was admitted because of a persistent fever, and elevated serum level of AST, ALT, LDH, and CRP. DIAGNOSIS: The patients met the diagnostic criteria for KD based on the findings of persistent fever, polymorphous exanthema, unilateral cervical lymphadenopathy, non-purulent palpebral conjunctivitis and membranous desquamation. Echocardiogram revealed the dilatation at the proximal sites of the right coronary artery (7.9âmm) and left anterior descending artery (5âmm). The patient was treated with high-dose intravenous immunoglobulin (1âg/kg/day for 2 days) and ASA (100âmg daily). However, his fever and arthralgia persisted. INTERVENTIONS: He was administered single 5âmg/kg doses of IFX. OUTCOMES: He became afebrile the next day and his arthralgia improved. LESSONS: We report the first case of administration of IFX in a patient with AKD refractory to intravenous immunoglobulin (IVIG), and successful reduction of systemic inflammation. However, the effectiveness of IFX in the regression of coronary artery aneurysm remains to be determined.
Subject(s)
Antirheumatic Agents/administration & dosage , Infliximab/administration & dosage , Mucocutaneous Lymph Node Syndrome/drug therapy , Age of Onset , Humans , Male , Treatment Outcome , Young AdultABSTRACT
Kawasaki disease (KD) is the most common cause of acquired heart disease with unknown etiology among children in developed countries. Acute inflammation of the vasculature, genetic susceptibility and immunopathogenesis based on a transmittable and infectious origin, are the pathologic events involved in the early inflammatory etiology and progression of this disease. However, the exact causes of KD remain unknown. Current proposed recommendations include three therapy lines; firstly, an initial standard therapy with intravenous immunoglobulin (IVIG) followed by aspirin. Secondly, in cases of high risk of coronary lesions, the adjunctive therapy with corticosteroid is commonly considered. Thirdly, in KD patients refractory to the previous therapies, tumor necrosis factor (TNF-α) antagonists are being used to modulate pro-inflammatory cytokines. In view of this status quo, our starting hypothesis is that the ubiquitous and non-toxic neurohormone melatonin could be of critical importance in developing novel adjuvant therapies against KD, as it occurs with a plethora of other diseases. Considering its pleiotropic properties, particularly its antiinflammatory and immunoregulatory capacities, melatonin should be of great therapeutic interest for helping to control the main pathologic features of KD patients. In addition, this multifunctional indole has a safe pharmacological profile, enhancing the therapeutic activity of several drugs and reducing their possible side effects. Consequently, melatonins actions to manage KD need to be tested in further clinical studies.
Subject(s)
Melatonin/therapeutic use , Mucocutaneous Lymph Node Syndrome/drug therapy , Anti-Inflammatory Agents/therapeutic use , Aspirin/therapeutic use , Child , Child, Preschool , Communicable Diseases/metabolism , Genetic Predisposition to Disease , Humans , Immunoglobulins, Intravenous/therapeutic use , Infant , Inflammation , Oxidative Stress , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
Kawasaki disease (KD) is an acute systemic vasculitis presenting as an infantile febrile disease. In Japan, the widespread cedar plantation commenced in 1945 has been correlated with the increased incidences of both KD and allergic rhinitis (pollinosis) since the early 1960s. We previously showed that KD was a pollen-induced, delayed-type hypersensitivity that displays biphasic peaks in both summer and winter. KD incidences decrease suddenly around February, particularly after influenza epidemics. Here we investigated the reason for a drastic decrease in KD onsets directly before spring pollen release following rapid increase after autumn pollen release leading to the biphasic pattern. We separately analyzed weekly incidences of KD and influenza in Tokyo (1987-2010) and Kanagawa (1991-2002). Repeated measures for the analysis of variance followed by Bonferroni's multiple comparison tests were performed to compare KD incidence over 3 consecutive weeks, including the weeks when the mean KD prevalence showed the steepest decrease. Next, the week with peak influenza incidence was reset for each year. KD incidence over 3 consecutive weeks, including the new origin week (adjusted week 0), was similarly analyzed. In Tokyo and Kanagawa, KD incidence significantly decreased only after resetting the influenza peak time. These findings suggested that influenza epidemics suppressed KD onset.
Subject(s)
Epidemics , Influenza, Human/epidemiology , Mucocutaneous Lymph Node Syndrome/epidemiology , Mucocutaneous Lymph Node Syndrome/immunology , Cedrus/adverse effects , Cedrus/immunology , Child , Humans , Incidence , Influenza Vaccines/administration & dosage , Interferon-beta/administration & dosage , Japan/epidemiology , Mucocutaneous Lymph Node Syndrome/drug therapy , Mucocutaneous Lymph Node Syndrome/prevention & control , Pollen/adverse effects , Pollen/immunology , Seasons , Time FactorsABSTRACT
Using whole exome sequencing, we confirmed a diagnosis of biotin-responsive basal ganglia disease (BBGD) accompanied by possible Kawasaki Disease. BBGD is an autosomal-recessive disease arising from a mutation of the SLC19A3 gene encoding the human thiamine transporter 2 protein, and usually manifests as subacute to acute encephalopathy. In this case, compound heterozygous mutations of SLC19A3, including a de novo mutation in one allele, was the cause of disease. Although a large number of genetic neural diseases have no efficient therapy, there are several treatable genetic diseases, including BBGD. However, to achieve better outcome and accurate diagnosis, therapeutic analysis and examination for disease confirmation should be done simultaneously. We encountered a case of possible Kawasaki disease, which had progressed to BBGD caused by an extremely rare genetic condition. Although the prevalence of BBGD is low, early recognition of this disease is important because effective improvement can be achieved by early biotin and thiamine supplementation.
Subject(s)
Basal Ganglia Diseases/diagnosis , Biotin/therapeutic use , Mucocutaneous Lymph Node Syndrome/diagnosis , Basal Ganglia Diseases/drug therapy , Basal Ganglia Diseases/genetics , DNA Mutational Analysis , Exome , Humans , Infant , Male , Membrane Transport Proteins/genetics , Molecular Diagnostic Techniques , Mucocutaneous Lymph Node Syndrome/drug therapyABSTRACT
Kawasaki disease (KD) is a self-limited childhood systemic vasculitis that exhibits a specific predilection for the coronary arteries. KD predominantly affects young children between the ages of 6months and 4years. Incidence rates in Asians are up to 20 times higher than Caucasians. The aetiology of KD is not known. One reasonable open hypothesis is that KD is caused by an infectious agent that produces an autoimmune disease only in genetically predisposed individuals. The typical presentation of KD is a young child who has exhibited a high swinging fever for five or more days that persists despite antibiotic and/or antipyretic treatment. The lips are dry and cracked. There is a characteristic strawberry tongue, and a diffuse erythema of oropharyngeal mucosal surfaces. Lymphadenopathy is usually unilateral and confined to the anterior cervical triangle. Coronary aneurysms generally appear during the convalescence phase (beginning during the second week). The absence of any laboratory tests for KD means that the diagnosis is made by the presence of a constellation of clinical features. The aim of echocardiography is to assess the presence of coronary artery dilatation or aneurysm formation. Effective therapies exist for most patients with acute KD, but the exact mechanisms of action are not clear. Treatment with aspirin and intravenous immunoglobulins (IVIG) are first-line therapies. However, options are plentiful for the children who fail this treatment, but these treatments are not as beneficial. Some centres attempt to salvage resistant patients using intravenous pulsed doses of methylprednisolone. Other centres use infliximab or combinations of these approaches.
Subject(s)
Mucocutaneous Lymph Node Syndrome/immunology , Aspirin/therapeutic use , Diagnosis, Differential , Fever , Humans , Immunoglobulins, Intravenous/therapeutic use , Mucocutaneous Lymph Node Syndrome/drug therapy , Mucocutaneous Lymph Node Syndrome/epidemiology , PrognosisABSTRACT
No disponible
Subject(s)
Humans , Arteritis/drug therapy , Vasculitis/drug therapy , Steroids/therapeutic use , Azathioprine/therapeutic use , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Mucocutaneous Lymph Node Syndrome/drug therapy , Takayasu Arteritis/drug therapy , Methotrexate/therapeutic use , Biological TherapyABSTRACT
The aim of this study was to explore the effect of pachyman, a mushroom extract, on CD4+CD25+ regulatory T cells (Tregs), serum interleukin 4 (IL-4) and interferon γ (IFN-γ) levels in a mouse model of Kawasaki disease. Lactobacillus casei cell wall extract was diluted to 1 mg/ml in PBS and administered to mice by intraperitoneal injection to establish a model of Kawasaki disease. Sixty female mice were used in this study, 40 of which were randomly assigned to a model (normal saline by gavage, n=20) or experimental group (200 mg/kg/day pachyman by gavage, n=20). The remaining 20 mice were disease and treatment-free, and were used as the control group. Compared to the control mice, mice in the model group exhibited a significantly lower percentage of CD4+CD25+ Tregs and significantly higher serum IL-4 and IFN-γ levels (P<0.05). However, CD4+CD25+ Tregs significantly increased and IL-4 and IFN-γ levels significantly decreased in experimental mice following pachyman treatment (P<0.05). Further analysis showed a negative correlation between CD4+CD25+ Tregs and IL-4/IFN-γ levels (P<0.05). In conclusion, pachyman improves immune function in a mouse model of Kawasaki disease by upregulating CD4+CD25+ Tregs, which may inhibit the cytokine secretion of Th1 and Th2 cells.
Subject(s)
Glucans/pharmacology , Interferon-gamma/blood , Interleukin-4/blood , Mucocutaneous Lymph Node Syndrome/drug therapy , T-Lymphocytes, Regulatory/metabolism , Animals , CD4 Lymphocyte Count , Cell Wall/chemistry , Complex Mixtures/chemistry , Complex Mixtures/toxicity , Disease Models, Animal , Female , Humans , Lacticaseibacillus casei/chemistry , Mice , Mice, Inbred BALB C , Mucocutaneous Lymph Node Syndrome/blood , Mucocutaneous Lymph Node Syndrome/chemically induced , Th1 Cells/metabolism , Th2 Cells/metabolismABSTRACT
Kawasaki disease constitutes an acute febrile vasculitis of unknown aetiology. It is considered the most common cause of acquired cardiac failure in children. Although standard treatment comprises intravenous immunoglobulin and aspirin, some children exhibit refractory disease, necessitating the use of alternative therapies such as corticosteroids and anti-tumour necrosis factor-alpha. For these cases, few controlled data are available. This report focuses on an extremely refractory classical Kawasaki disease with coronary artery aneurysms and ongoing inflammation. We discuss the therapeutic approaches and the potential pitfalls undertaken, which led to an unfavourable clinical outcome.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/therapeutic use , Coronary Aneurysm/etiology , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Mucocutaneous Lymph Node Syndrome/drug therapy , Coronary Aneurysm/diagnostic imaging , Echocardiography , Fatal Outcome , Female , Fever/etiology , Humans , Infant , Inflammation , Mucocutaneous Lymph Node Syndrome/complications , Mucocutaneous Lymph Node Syndrome/diagnostic imaging , Myocardial Ischemia/etiologyABSTRACT
Several biological therapies have been evaluated in systemic vasculitis. Anti TNF-α agents may have a role in the treatment of Takayasu's arteritis and probably in giant cell arteritis. In Kawasaki's disease, infliximab is an option in subjects with intravenous immunoglobulin-resistant disease. Anti TNF-α cannot be recommended to treat ANCA-associated vasculitis. Anti-T lymphocyte globulin and alemtuzumab could have a role in the treatment of ANCA associated vasculitis, although current information about these two biological treatments comes from conventional resistant treatment cases, so the high incidence of complications and relapses observed with these treatment may be intrinsic to the severity of the disease and not related to the biological agents.
Subject(s)
Biological Therapy , Systemic Vasculitis/drug therapy , Alemtuzumab , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antilymphocyte Serum/therapeutic use , Etanercept , Giant Cell Arteritis/drug therapy , Humans , Immunoglobulin G/therapeutic use , Infliximab , Interferon-alpha/therapeutic use , Mucocutaneous Lymph Node Syndrome/drug therapy , Receptors, Tumor Necrosis Factor/therapeutic use , Receptors, Tumor Necrosis Factor, Type II/antagonists & inhibitors , T-Lymphocytes , Takayasu Arteritis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
Varias terapias biológicas se han probado en las vasculitis sistémicas. Los anti-TNF- pudieran tener un papel en el tratamiento de la arteritis de Takayasu y probablemente en la arteritis de células gigantes. En el caso de la enfermedad de Kawasaki, existe información de que el infliximab puede ser usado como una alternativa a la gammaglobulina por vía intravenosa en pacientes sin respuesta a una primera dosis de ésta. No se puede recomendar el uso de anti TNF- en las vasculitis asociadas a ANCA. La gammaglobulina antitimocito y el alemtuzumab pudieran tener algún papel en el tratamiento de las vasculitis asociadas a ANCA. La información existente acerca de la utilidad de estos dos fármacos proviene de casos refractarios al tratamiento convencional, por lo que la alta incidencia de complicaciones y recaídas observadas en los casos tratados con estos fármacos pudiera ser más bien intrínseca a la gravedad de la enfermedad y no debida a los agentes biológicos (AU)
Several biological therapies have been evaluated in systemic vasculitis. Anti TNF- agents may have a role in the treatment of Takayasus arteritis and probably in giant cell arteritis. In Kawasakis disease, infliximab is an option in subjects with intravenous immunoglobulin-resistant disease. Anti TNF- cannot be recommended to treat ANCA-associated vasculitis. Anti-T lymphocyte globulin and alemtuzumab could have a role in the treatment of ANCA associated vasculitis, although current information about these two biological treatments comes from conventional resistant treatment cases, so the high incidence of complications and relapses observed with these treatment may be intrinsic to the severity of the disease and not related to the biological agents (AU)
Subject(s)
Humans , Antilymphocyte Serum/therapeutic use , Biological Therapy , Systemic Vasculitis/drug therapy , Giant Cell Arteritis/drug therapy , Immunoglobulin G/therapeutic use , Interferon-alpha/therapeutic use , Mucocutaneous Lymph Node Syndrome/drug therapy , Receptors, Tumor Necrosis Factor/therapeutic use , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Receptors, Tumor Necrosis Factor, Type II/antagonists & inhibitors , T-Lymphocytes , Takayasu Arteritis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitorsSubject(s)
Antibodies, Monoclonal/administration & dosage , Immunotherapy , Mucocutaneous Lymph Node Syndrome/drug therapy , Antibodies, Monoclonal/adverse effects , Conjunctivitis , Disease-Free Survival , Drug Resistance , Exanthema , Fever , Humans , Immunoglobulins, Intravenous/therapeutic use , Infant , Infliximab , Lymphatic Diseases , Male , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/physiopathology , Remission Induction , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunologyABSTRACT
A 3 yr old boy presented with abdominal pain, fever and red jelly stools. Intussusception was diagnosed and effectively reduced with air insufflation. However, despite an improvement in his clinical condition, the child remained febrile and miserable; 5 days later he developed characteristic signs of Kawasaki disease and was treated with intravenous immunoglobulin and high dose aspirin with good results. Intussusception prior to the typical features of Kawasaki disease has not been described previously in the English literature. This case illustrates a novel presentation of Kawasaki disease.
Subject(s)
Intussusception/etiology , Mucocutaneous Lymph Node Syndrome/complications , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/administration & dosage , Aspirin/therapeutic use , Child, Preschool , Dose-Response Relationship, Drug , Drug Therapy, Combination , Enema , Follow-Up Studies , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Insufflation/methods , Intussusception/diagnosis , Intussusception/therapy , Male , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapyABSTRACT
Approximately 15-20% of patients with Kawasaki disease (KD) are not responsive to high-dose intravenous gammaglobulin (IVIG). We have previously reported a predictive method for identifying IVIG-non-responsive patients (high-risk KD patients). We determined the safety and effectiveness of pulse methylprednisolone with high-dose IVIG (mPSL+IVIG) as a primary treatment for high-risk KD patients. Sixty-two high-risk KD patients were treated with pulse methylprednisolone 30 mg/kg over 2 h, followed by IVIG 2 g/kg over 24 h (mPSL+IVIG group) and were compared with a historical control group of 32 high-risk patients treated with IVIG 2 g/kg alone at the participating hospitals before this study was opened (IVIG group). High-risk patients were identified with at least two of three predictors (C-reactive protein >or=7 mg/dL, total bilirubin >or=0.9 mg/dL or aspartate aminotransferase >or=200 IU/L). Sixty-six percent (95% confidence interval [CI] 54-78%) of patients had a prompt defervescence in the mPSL+IVIG group compared with 44% (95% CI 26-62%) for the IVIG group (p=0.048). Coronary artery lesions were observed in 24.2% (95% CI 13.2-35.2%) and 46.9% (95% CI 28.6-65.2%) of patients in the mPSL+IVIG and IVIG groups, respectively (p=0.025). This is the first report showing that mPSL+IVIG is effective and safe as a primary treatment for high-risk KD patients.
Subject(s)
Methylprednisolone/administration & dosage , Mucocutaneous Lymph Node Syndrome/drug therapy , gamma-Globulins/administration & dosage , Aspartate Aminotransferases/blood , Bilirubin/blood , C-Reactive Protein/metabolism , Child, Preschool , Coronary Artery Disease/diagnosis , Coronary Artery Disease/drug therapy , Coronary Artery Disease/enzymology , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Heparin/administration & dosage , Humans , Infant , Infusions, Intravenous , Male , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/enzymology , Pulse Therapy, Drug , Risk Factors , Treatment OutcomeABSTRACT
BACKGROUND: There are few studies of the therapeutic regimens for the prevention of stenotic transformation of aneurysms in Kawasaki disease (KD). The aim of this study was to assess the prophylactic effect of combined therapy in the acute stage and convalescent- to chronic-stage against the formation of stenotic lesions. METHODS AND RESULTS: In 85 patients, 103 giant aneurysms (ANl), 46 medium-sized aneurysms (ANm), and 13 small aneurysms (ANs) were analyzed. With respect to therapy in the acute stage, no localized stenosis of ANl in the left coronary artery was noted in patients who received high-dose gamma globulin therapy (G). For ANm, the group (G) showed a significantly higher regression rate than the aspirin group and steroids group. Furthermore, no coronary artery occlusion/recanalization of ANl occurred with the prophylactic regimen of aspirin and warfarin {aw}. Prophylaxis {aw} and the prophylactic regimen of aspirin alone {a} significantly lowered the incidence compared with either the prophylactic regimen of warfarin {w} or no prophylaxis {n}. However, no significant differences were noted between prophylaxis {w} and {n}. CONCLUSIONS: High-dose gamma globulin therapy in the acute stage of KD is the first choice for the prevention of stenotic transformation. Prophylaxis {aw} is recommended for ANl.
Subject(s)
Coronary Aneurysm/drug therapy , Mucocutaneous Lymph Node Syndrome/complications , gamma-Globulins/administration & dosage , Acute Disease , Aspirin/therapeutic use , Coronary Aneurysm/pathology , Coronary Stenosis/prevention & control , Humans , Longitudinal Studies , Mucocutaneous Lymph Node Syndrome/drug therapy , Prednisolone/administration & dosage , Prednisolone/therapeutic use , Retrospective Studies , Warfarin/therapeutic use , gamma-Globulins/therapeutic useABSTRACT
La enfermedad de Kawasaki es una arteritis sistémica que afecta predominantemente a los niños < 5 años de edad y cuya etiopatogenia permanece desconocida. En los países desarrollados, ha sustituido a la fiebre reumática como principal causa de cardiopatía adquirida en la infancia. El diagnóstico se basa fundamentalmente en los hallazgos clínicos. El tratamiento específico con dosis altas de gammaglobulina IV y aspirina en los primeros diez días de la enfermedad o mientras persista la fiebre reduce el riesgo de complicaciones cardiovasculares de un 20-25 por ciento a un 3-4 por ciento. En este artículo se revisa la epidemiología, etiologías posibles, manifestaciones clínicas y tratamiento de la enfermedad de Kawasaki (AU)